Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

This publication has 22 references indexed in Scilit:

• Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
  Endocrinology, 1995
• Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer
  Cancer Letters, 1994
• Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound ¹²⁵I‐(Tyr⁴) bombesin by tumor cells
  The Prostate, 1994
• Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
  The Prostate, 1994
• Screening for prostate cancer—Necessity or nonsense?
  European Journal Of Cancer, 1993
• Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice
  International Journal of Cancer, 1993
• Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination
  Breast Cancer Research and Treatment, 1992
• Inhibitory Effects of the New Bombesin Receptor Antagonist RC-3095 on the Luteinizing Hormone Release in Rats
  Neuroendocrinology, 1992
• Interactions between epidermal growth factor-mediated autocrine regulation and linoleic acid-stimulated growth of a human prostate cancer cell line
  The Prostate, 1992
• Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
  Nature, 1985